Ecopipam Significantly Reduces Relapse Risk in Pediatric and Overall Populations With Tourette Syndrome

Ecopipam significantly reduces the risk of symptom relapse in children and adolescents with Tourette syndrome, according to new data from a phase 3 randomized withdrawal trial presented at the American Academy of Neurology 2026 Annual Meeting.

The findings, reported by Pharmacy Times and corroborated by multiple health science outlets, indicate that continued treatment with ecopipam, an investigational dopamine D1 receptor antagonist developed by Emalex Biosciences, provides durable control of tics without movement-related adverse effects.

In the phase 3 study, patients who had previously responded to ecopipam were randomized to either continue the medication or switch to placebo. Those who remained on ecopipam experienced a approximately 50% reduction in relapse risk compared to the placebo group, demonstrating sustained efficacy over time.

This builds on earlier phase 2 results, which showed that ecopipam reduced tic severity by 30% after 12 weeks in a cohort of 150 children and adolescents with Tourette syndrome. The phase 3 trial confirms that these benefits are maintained with longer-term use and that discontinuation significantly increases the likelihood of symptom return.

Unlike some existing treatments for Tourette syndrome, ecopipam has not been associated with movement-related side effects such as parkinsonism or tardive dyskinesia in clinical trials to date, a distinguishing feature attributed to its selective mechanism as a D1 receptor antagonist.

Tourette syndrome is a neurodevelopmental disorder characterized by involuntary motor and vocal tics, often beginning in childhood. While behavioral therapies and certain medications can help manage symptoms, many patients experience incomplete response or intolerable side effects, highlighting the need for alternative therapeutic options.

Emalex Biosciences has positioned ecopipam as a potential precision medicine approach for Tourette syndrome, targeting the dopaminergic pathways implicated in tic generation. The company continues to evaluate the drug’s long-term safety and efficacy, with regulatory submissions anticipated pending further data.

As of April 22, 2026, ecopipam remains an investigational agent and has not yet received approval from the U.S. Food and Drug Administration. The results from the phase 3 trial represent a key step in the clinical development program, offering evidence of both efficacy and durability in a pediatric population historically underserved by novel treatments.